Takeda Raises Full-Year, Entyvio Forecasts On Solid H1
On Look Out For R&D Assets
While it is benefiting handsomely from the near 50-year low of the yen, Takeda said strong underlying growth for its mainstays in the fiscal first half was one factor behind its raised full-year forecast, and the Japanese major also sees a brighter long-term outlook for global blockbuster Entyvio.
